You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/Aepsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/Aepsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND
SBC: ANDROSCIENCE CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A SYSTEM FOR MEASURING PELVIC MUSCLE STRENGTH IN WOMEN
SBC: BIO LOGIC ENGINEERING, INC. Topic: N/ADESCRIPTION (provided by applicant): One in nine women suffer from pelvic floor dysfunction, including urinary incontinence and vaginal wall or uterine prolapse (VUP). Stress urinary incontinence (SUI) affects 38% of women over the age of 65 years and over 13 million women in the United States. Pelvic muscle strength is commonly assessed in these patients. However, current measurement techniques a ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A SYSTEM FOR MEASURING PELVIC MUSCLE STRENGTH IN WOMEN
SBC: BIO LOGIC ENGINEERING, INC. Topic: N/ADESCRIPTION (provided by applicant): One in nine women suffer from pelvic floor dysfunction, including urinary incontinence and vaginal wall or uterine prolapse (VUP). Stress urinary incontinence (SUI) affects 38% of women over the age of 65 years and over 13 million women in the United States. Pelvic muscle strength is commonly assessed in these patients. However, current measurement techniques a ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
NASALLY-DELIVERED MUCOSAL SUBUNIT VACCINE FOR PLAGUE
SBC: BIODEFENSE TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): We have developed a plant-based adjuvant/carrier:antigen fusion technology that offers significant advantages over conventional injectable vaccination regimes including: safety, mucosal efficacy, ease of delivery, rapid scalability, unlimited supply potential, and cost-savings. This technology has significant potential in contributing to biodefense strategies ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A HOMOGENEOUS TRANSMIT COIL FOR HIGH FIELD HUMAN NMR
SBC: BIOENGINEERING, INC. Topic: N/ADESCRIPTION (provided by applicant): In this Phase II STTR project, the investigators plan to extend their successful Phase I feasibility demonstration to the development and manufacture of an RF body coil plus phased array receive system for use in high field clinical and research MRI systems. In Phase I, the feasibility of a large homogeneous transmit coil based on the TEM design was proven, pub ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
A HOMOGENEOUS TRANSMIT COIL FOR HIGH FIELD HUMAN NMR
SBC: BIOENGINEERING, INC. Topic: N/ADESCRIPTION (provided by applicant): In this Phase II STTR project, the investigators plan to extend their successful Phase I feasibility demonstration to the development and manufacture of an RF body coil plus phased array receive system for use in high field clinical and research MRI systems. In Phase I, the feasibility of a large homogeneous transmit coil based on the TEM design was proven, pub ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
FORMULATION AND EVALUATION OF A PROSTATE CANCER DRUG
SBC: Biomide Corporation Topic: N/AMetabolism of arichidonic acid by 12-lipoxygenase results in the formation of 12(s)-hydroxy eicosatetraenoic acid, which exhibits profound biological activity and plays an important role in tumor cell survival, angiogenesis, and metastases. Prostate cancer is the most commonly diagnosed neoplasm and second leading cause of male death in the United States. Human prostate cancer cells express incre ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health